Results 61 to 70 of about 5,411,820 (260)

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland [PDF]

, 2018
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis.
Calabrese, Pasquale, Rodgers, S., Kaufmann, Marco; https://orcid.org/, Kuhle, J., Puhan, M.A., Puhan, Milo A, Kuhle, Jens, Puhan, M. A., Kamm, Christian P, Kesselring, Jürg, Rodgers, Stephanie, Pot, Caroline, Steinemann, Nina, von Wyl, Viktor, Kamm, C.P., von Wyl, V., Salmen, A., Pot, C., Salmen, Anke, Steinemann, N., Kaufmann, M., Chan, A., Kamm, Christian Philipp, Chan, Andrew, Gobbi, C., Gobbi, Claudio, Kesselring, J., Calabrese, P.   +27 more
core   +2 more sources

Comparing the Effect of Semi‐Immersive Virtual Reality, Computerized Cognitive Training, and Traditional Rehabilitation on Cognitive Function in Multiple Sclerosis: A Randomized Clinical Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio, Desiree Latella, Lilla Bonanno, Paulo Cezar Rocha dos Santos, Marcos Maldonado‐Díaz, Meir Plotnik, Rosaria De Luca, Angelo Quartarone, Rocco Salvatore Calabrò   +8 more
wiley   +1 more source

Optimization of therapy in secondary progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика
The article provides an analysis of modern methods of treatment of secondary progressive multiple sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations and without exacerbations) is siponimod. Clinical
A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov   +2 more
doaj   +1 more source

PARP-1 deregulation in multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Poly (ADP-ribose) polymerase 1 (PARP-1) plays pivotal roles in immune and inflammatory responses. Accumulating evidence suggests PARP-1 as a promising target for immunomodulation in multiple sclerosis and natalizumab-associated progressive ...
Maria Meira, Claudia Sievers, Francine Hoffmann, Heidi Bodmer, Tobias Derfuss, Jens Kuhle, Aiden Haghikia, Ludwig Kappos, Raija LP Lindberg   +8 more
doaj   +1 more source

No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis [PDF]

, 2013
Mitochondrial dysfunction is an established feature of multiple sclerosis (MS). We recently described high levels of mitochondrial DNA (mtDNA) deletions within respiratory enzyme-deficient (lacking mitochondrial respiratory chain complex IV with intact ...
Turnbull, Doug M, Reeve, Amy K, Ziabreva, Iryna, Campbell, Graham R, Reynolds, Richard, Mahad, Don J   +5 more
core   +1 more source

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng, Diego Z. Carvalho, Shahid Karim, Anwar Chahal, Virend K. Somers   +4 more
wiley   +1 more source

Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis

Neural Regeneration Research, 2017
Unlike relapsing remitting multiple sclerosis, there are very few therapeutic options for patients with progressive forms of multiple sclerosis. While immune mechanisms are key participants in the pathogenesis of relapsing remitting multiple sclerosis ...
Rebecca M Heidker, Mitchell R Emerson, Steven M LeVine   +2 more
doaj   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)—Results of a Pilot Randomized Controlled Trial

Frontiers in Neurology, 2021
Background: Walking disability is one of the most frequent and burdening symptoms of progressive multiple sclerosis (MS). Most of the exercise intervention studies that showed an improvement in mobility performance were conducted in low to moderately ...
Inga Heinrich, Friederike Rosenthal, Stefan Patra, Karl-Heinz Schulz, Götz H. Welsch, Eik Vettorazzi, Sina C. Rosenkranz, Sina C. Rosenkranz, Jan Patrick Stellmann, Jan Patrick Stellmann, Jan Patrick Stellmann, Caren Ramien, Jana Pöttgen, Jana Pöttgen, Stefan M. Gold, Stefan M. Gold, Stefan M. Gold, Christoph Heesen, Christoph Heesen   +18 more
doaj   +1 more source

Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran, Malo Gaubert, Alice Dufey, Elise Bannier, Audrey Rico, Jean‐Christophe Ferré, Raphaël Chouteau, Laure Michel, Emmanuelle Le Page, Virginie Callot, Bertrand Audoin, Sarah Demortière, Benoît Combès, Anne Kerbrat   +13 more
wiley   +1 more source